<DOC>
	<DOCNO>NCT01602315</DOCNO>
	<brief_summary>This multi-center , open-label , Phase Ib dose escalation / Phase II study recurrent metastatic head neck squamous cell carcinoma ( RM HNSCC ) patient consider resistant , ineligible intolerant platinum-based chemotherapy . The first aim Phase Ib determine Maximum Tolerated Dose ( ) ( MTD ( ) ) and/or Recommended Phase II Dose ( ) ( RP2D ( ) ) BYL719 combination cetuximab This part include two different arm use two different administration method BYL719 tablets together cetuximab recommend label : Arm A - whole tablet administer patient able swallow tablet vs . Arm B - drinkable suspension prepare crushed tablet administer patient swallow dysfunction . The second aim Phase Ib compare pharmacokinetics ( PK ) new dispersible tablet formulation BYL719 combination cetuximab . A third arm open : Arm C , use suspension dispersible tablet administer via gastric feed tube ( G tube ) . The safety , tolerability , PK , PD , efficacy investigate separately Phase Ib arm . The MTD/RP2D investigate independently Arm A B . The one Arm B compare Arm A . If MTD/RP2D , administration method BYL719 may use Phase II . If MTD/RP2D different , administration BYL719 whole tablet allow Phase II . Arm C independent relative bioavailability study new dispersible tablet formulation BYL719 , begin start dose/RP2D identify safety cohort follow expansion cohort . There dose escalation de-escalation Arm . If either safety pharmacokinetic profile RP2D 300 mg QD Arm C comparable Arm A , enrollment Arm C cease dispersible tablet implement Phase II . The Phase Ib dose escalation part expect enroll approximately 12 patient Arm A B guide Bayesian logistic regression model ( BLRM ) . The available safety , tolerability , PK , PD efficacy data , well recommendation BLRM , use determine dose combination next cohort ( ) . The Phase II part study commence upon MTD/RP2D declaration Arm A Phase Ib , regardless progress Arm B C. The Phase II part ass clinical efficacy BYL719 combination cetuximab two patient population : patient assign one two scheme enrollment base prior therapy cetuximab . Patients consider cetuximab naïve per protocol assign Scheme 1 . The primary purpose scheme assess anti-tumor activity BYL719 combination cetuximab ( Arm 1 ) vs. cetuximab single-agent ( Arm 2 ) RM HNSCC patient ' naïve cetuximab . Patients scheme 1 randomize 2:1 ratio via IRT two Phase II arm : BYL719 combination cetuximab ( Arm 1 ) vs. cetuximab single-agent ( Arm 2 ) . Patients randomize Arm 2 ( cetuximab monotherapy ) opportunity cross-over combination treatment BYL719 + cetuximab experience disease progression . Arm 1 consist approximately 66 patient Arm 2 approximately 33 patient . Patients receive prior cetuximab per protocol assign Scheme 2 . The primary purpose scheme assess anti-tumor activity BYL719 combination cetuximab RM HNSCC cetuximab resistant patient ( Arm 3 ) . Patients scheme randomize . 40 patient enrol . Phase II characterize safety PK drug combination . Patients treated progression disease ( except phase II Arm 2 ) , unacceptable toxicity , withdrawal informed consent , whichever occur first . Patients enrol Arm 2 experience disease progression opportunity crossover combination treatment ( Arm 2B ) continue experience unacceptable toxicity precludes treatment , disease progression , and/or treatment discontinue discretion Investigator patient refusal . In follow-up period patient must complete safety follow-up assessment 30 day last dose study treatment . Patients progressed time discontinuation study treatment radiologically follow disease status disease progression , initiation subsequent anticancer therapy , death , whichever occur first . In addition , patient enrol Phase II follow survival .</brief_summary>
	<brief_title>A Phase Ib/II Study BYL719 Cetuximab Recurrent Metastatic Head Neck Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Age ≥ 18 year Patients histologically/cytologicallyconfirmed HNSCC Patients must resistant platinumbased chemotherapy , ineligible ( due medical comorbidities ) intolerant platinumbased therapy per medical history For Phase Ib , restriction number prior therapy recurrent metastatic disease For Phase II , patient may receive maximum 1 prior line therapy recurrent metastatic disease For Phase Ib , prior cetuximab EGFRtargeted antibody therapy allow regardless prior treatment setting . For Phase II , Arms 1 2 , prior cetuximab EGFRtargeted antibody therapy allow administered induction setting , concurrently radiation curative setting , last dose cetuximab administer least 12 month prior start study treatment . For Arm 3 , prior cetuximab must administer curative , recurrent metastatic disease set disease progression document within 9 month last dose cetuximab administer set . This regimen ( include platinum cetuximab ) must recent antineoplastic treatment regimen administer . Patients swallow dysfunction unable swallow BYL719 whole tablet use feed tube study drug administration participate Phase Ib Arm B . For Phase II , patient swallow dysfunction may participate able drink suspension result Arm B confirm use method . Patients swallow dysfunction require G tube ( G/PEG tube ) study drug administration may participate Phase II Arm C confirm dispersible tablet via G tube administration permit administration drinkable suspension BYL719 allow use Phase II . Availability representative tumor specimen . Patients enrol Arm 3 Phase II must disease site amenable biopsy unless prior agreement Novartis Investigator . At least one measurable nonmeasurable lesion per RECIST 1.1 criterion patient Phase Ib ; Measurable disease determine RECIST v1.1 Phase II patient World Health Organization ( WHO ) Performance Status ( PS ) ≤ 2 Adequate organ function Negative serum pregnancy test . Prior treatment PI3Kinhibitors Patients prior serious infusion reaction cetuximab Patients uncontrolled CNS tumor metastatic involvement Clinically significant cardiac disease impair cardiac function Patients diabetes mellitus Impaired GI function GI disease History another malignancy within 2 year prior start study treatment Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>BYL719</keyword>
	<keyword>PI3K inhibitor</keyword>
	<keyword>PIK3CA</keyword>
	<keyword>cetuximab</keyword>
	<keyword>EGFR</keyword>
	<keyword>HNSCC</keyword>
	<keyword>RM HNSCC</keyword>
	<keyword>platinum-based chemotherapy</keyword>
	<keyword>( RM HNSCC ) patient</keyword>
	<keyword>resistant ineligible/intolerant platinum-based chemotherapy</keyword>
	<keyword>swallow dysfunction</keyword>
	<keyword>G-tube</keyword>
</DOC>